| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, …
Over the last 12 months, insiders at Sutro Biopharma, Inc. have bought $0 and sold $0 worth of Sutro Biopharma, Inc. stock.
On average, over the past 5 years, insiders at Sutro Biopharma, Inc. have bought $122,287 and sold $93,401 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 12,500 shares for transaction amount of $10,011 was made by Chung Jane (Chief Executive Officer) on 2025‑10‑15.
| 2025-10-15 | Chung Jane | Chief Executive Officer | 12,500 0.0151% | $0.80 | $10,011 | +162.56% | ||
| 2025-10-15 | Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | 17,000 0.0206% | $0.80 | $13,607 | +162.56% | ||
| 2025-10-15 | Pauling David | Chief Admin. Ofcr. & GC | 12,504 0.0151% | $0.80 | $9,993 | +162.56% | ||
| 2025-10-15 | MATSUI CONNIE | director | 50,000 0.0604% | $0.80 | $39,950 | +162.56% | ||
| 2025-10-15 | Chow Gregory K. | CFO | 19,750 0.0242% | $0.81 | $15,998 | +162.56% | ||
| 2024-01-29 | Sale | Vasquez Nicki | CHIEF PORT. STRAT & ALNCE OFCR | 12,185 0.0202% | $5.00 | $60,925 | -24.45% | |
| 2023-08-28 | Sale | Shtylla Brunilda | Chief Business Officer | 15,428 0.0253% | $4.71 | $72,595 | -16.67% | |
| 2023-08-25 | Sale | Shtylla Brunilda | Chief Business Officer | 11,613 0.0191% | $4.59 | $53,282 | -14.35% | |
| 2022-03-14 | NEWELL WILLIAM J | CEO | 20,000 0.0428% | $7.75 | $155,016 | -20.05% | ||
| 2021-09-28 | Sale | Vasquez Nicki | Chief Port. Strat & Alnce Ofcr | 7,812 0.0168% | $18.62 | $145,449 | -56.52% | |
| 2021-01-26 | Sale | Hallam Trevor | Chief Scientific Officer | 4,786 0.0109% | $25.71 | $123,056 | -22.66% | |
| 2020-12-28 | Sale | Hallam Trevor | Chief Scientific Officer | 4,786 0.0079% | $13.36 | $63,964 | -11.14% | |
| 2020-11-27 | Sale | Hallam Trevor | Chief Scientific Officer | 4,786 0.0081% | $10.69 | $51,147 | +17.02% | |
| 2020-11-05 | Sale | Hallam Trevor | Chief Scientific Officer | 33,502 0.061% | $9.68 | $324,299 | +38.31% | |
| 2020-09-28 | Sale | Hallam Trevor | Chief Scientific Officer | 1,950 0.0053% | $10.26 | $20,013 | +91.08% | |
| 2020-09-18 | Sale | Freund John Gordon | director | 800,000 2.1944% | $12.00 | $9.6M | +65.94% | |
| 2020-09-11 | Sale | Freund John Gordon | director | 1M 2.6591% | $10.00 | $10M | +89.21% | |
| 2020-08-26 | Sale | Hallam Trevor | Chief Scientific Officer | 975 0.0026% | $9.04 | $8,818 | +101.61% | |
| 2020-08-19 | Sale | Freund John Gordon | director | 1M 2.5584% | $8.72 | $8.72M | +102.44% | |
| 2020-07-27 | Sale | Hallam Trevor | Chief Science Officer | 975 0.0026% | $8.06 | $7,858 | +124.43% |
| Merck & Co., Inc. | 10 percent owner | 2723509 16.4253% | $25.9M | 1 | 0 | <0.0001% |
| Chung Jane | Chief Executive Officer | 122850 0.7409% | $1.17M | 1 | 0 | +162.56% |
| NEWELL WILLIAM J | CEO | 116525 0.7028% | $1.11M | 2 | 0 | +40.88% |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | 71832 0.4332% | $683,122.32 | 1 | 0 | +162.56% |
| Pauling David | Chief Admin. Ofcr. & GC | 71737 0.4326% | $682,218.87 | 1 | 0 | +162.56% |
| MATSUI CONNIE | director | 50000 0.3015% | $475,500.00 | 1 | 0 | +162.56% |
| Chow Gregory K. | CFO | 19750 0.1191% | $187,822.50 | 1 | 0 | +162.56% |
| MOLINA ARTURO MD | Chief Medical Officer | 12083 0.0729% | $114,909.33 | 1 | 0 | +101.81% |
| FITZPATRICK LINDA A | Chief People & Comm. Officer | 9007 0.0543% | $85,656.57 | 1 | 0 | +101.81% |
$6,788,859 | 35 | 26.72% | $151.54M | |
$7,147,964 | 34 | 24.77% | $166.39M | |
$47,438,336 | 33 | -21.38% | $122.37M | |
$38,621,826 | 31 | 1.43% | $157.74M | |
$74,231,875 | 30 | 40.62% | $183.78M |
| Increased Positions | 26 | +19.85% | 2M | +32.24% |
| Decreased Positions | 60 | -45.8% | 1M | -27.32% |
| New Positions | 11 | New | 872,516 | New |
| Sold Out Positions | 32 | Sold Out | 843,706 | Sold Out |
| Total Postitions | 97 | -25.95% | 6M | +4.91% |
| Suvretta Capital Management, Llc | $7,111.00 | 7.21% | 648,832 | 0 | 0% | 2025-09-30 |
| Kynam Capital Management, Lp | $5,577.00 | 5.65% | 508,810 | 0 | 0% | 2025-09-30 |
| Millennium Management Llc | $4,959.00 | 5.03% | 452,435 | -20,789 | -4.39% | 2025-09-30 |
| Vanguard Group Inc | $4,037.00 | 4.09% | 368,299 | -43,226 | -10.5% | 2025-09-30 |
| Acadian Asset Management Llc | $3,715.00 | 3.77% | 338,932 | +34,708 | +11.41% | 2025-09-30 |
| Velan Capital Investment Management Lp | $3,420.00 | 3.47% | 312,000 | +6,000 | +1.96% | 2025-09-30 |
| Tang Capital Management Llc | $3,100.00 | 3.14% | 282,872 | +26,713 | +10.43% | 2025-09-30 |
| Merck & Co., Inc. | $2,985.00 | 3.03% | 272,351 | 0 | 0% | 2025-09-30 |
| Vestal Point Capital, Lp | $2,850.00 | 2.89% | 260,000 | 0 | 0% | 2025-09-30 |
| Eversept Partners, Lp | $2,511.00 | 2.55% | 229,131 | -95 | -0.04% | 2025-09-30 |